ClinicalTrials.gg
Not yet recruitingNCT06593119TM-HTNUpdated Oct 19, 2026

Tailoring TM-HTN Intervention for Black Patients

An interventional study of Telemedicine management of Hypertension and Usual Care in Hypertension, sponsored by Wake Forest University Health Sciences. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Hypertension by Wake Forest University Health Sciences — 4 open to participants now, 7 under way, none of them phase 3. Hypertension · Wake Forest University Health Sciences.

Planned enrollment
7th of 20
60 · median 41
Started
2026
with 2 others
No phase
17 of 25
3 open now
Registered
22nd of 25
by date

Among the 25 studies in Hypertension by Wake Forest University Health Sciences, this one is the 7th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2026, is one of 17 with no phase, and was the 22nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

4 of the 25 studies in Hypertension by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hypertension by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

Current clinic-based hypertension (HTN) management models have several limitations, resulting in episodic care that does not adequately support patients' self-care skills, and fails to achieve blood pressure (BP) control.

Read the detailed description

Telemedicine management of HTN (TM-HTN) can augment and overcome challenges by allowing more support for patients' HTN self-care skills, providing multiple home Blood Pressure values and overcoming failure to appropriately intensify treatment. TM-HTN consists of 1) home BP monitoring, 2) home BP based pharmacotherapy, and 3) telemedicine-based self-management support.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Telemedicine
  • socially disadvantaged
  • African American or Black patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be African American or Black
  • experiencing socially disadvantage
  • Patients with systolic Blood Pressure ≥140 mmHg on their last two clinic visits and baseline systolic BP >130 mmHg using the mean of two research BP values measured by trained staff
  • Subjects must be on stable Blood Pressure medications for the preceding 6 weeks

Exclusion criteria

Exclusion Criteria:

  • Unable to read or speak English
  • diminished ability to measure home Blood Pressure
  • chronic kidney disease ≥stage 4
  • persistent/chronic atrial fibrillation
  • severe hypertension >180/110 mmHg
  • acute health changes in past 3 months increasing chance of Blood Pressure instability
  • terminal illness
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Telemedicine management of Hypertension intervention group

    BP monitor and telehealth application Home BP monitoring Pharmacotherapy Telemedicine-based self-management support Additional support in-person training

    Behavioral: Telemedicine management of Hypertension

  • Placebo comparator
    control group

    This includes usual clinic based Hypertension care using routinely available clinic resources (e.g., community health worker, social worker). Clinicians can offer self-management support (e.g., dietician referral) or recommend a home BP monitor. These activities mirror current primary care practice.

    Behavioral: Usual Care

Interventions

  • BehavioralTelemedicine management of Hypertension

    TM-HTN intervention includes tailored and frequent self-management support, home blood pressure monitoring, pharmacotherapy, and as-needed assistance for health-related social needs provided by pharmacists, nurses, community health workers, and social workers. This will be compared with usual care

    Also known as: TM-HTN

  • BehavioralUsual Care

    This includes usual clinic based HTN care using routinely available clinic resources (e.g., community health worker, social worker). Clinicians can offer self-management support (e.g., dietician referral) or recommend a home BP monitor. These activities mirror current primary care practice.

    Also known as: Control Group

06

What researchers measure

Primary outcomes

  1. Proportion of patients who are screened

    Proportion of patients who are screened

    Time frame: Month 6

  2. Proportion of patients who are eligible

    Proportion of patients who are eligible

    Time frame: Month 6

  3. Proportion of patients who agree to participate

    Proportion of patients who agree to participate

    Time frame: Month 6

  4. Proportion of patients who decline

    Proportion of patients who decline

    Time frame: Month 6

  5. Number of staff needed and time spent for intervention

    staff training, technical support, troubleshooting

    Time frame: Month 6

  6. Proportion of completed self-measurement of Blood Pressure at home

    Proportion of completed self-measurement of BP at home

    Time frame: Month 6

  7. Proportion of completed self-management contacts.

    Proportion of completed self-management contacts.

    Time frame: Month 6

Secondary outcomes

  1. Change in Blood Pressure

    Effect size for BP change at 6-months (both arms)

    Time frame: Month 6

  2. Medication adherence

    Medication adherence using the Proportion of Days Covered and Domains of Subjective Extent of Nonadherence Measure (both arms)

    Time frame: Month 6

  3. Feasibility of Intervention Measure [FIM]

    measured on a 5-point Likert scale - 'excellent', 'good', 'fair' or 'poor' - higher scores denotes better feasibility

    Time frame: Month 6

  4. Acceptability of Intervention Measure [AIM]

    Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree)

    Time frame: Month 6

  5. Intervention Appropriateness Measure [IAM]

    The IAM uses a 5-point Likert scale, with scores ranging from "Completely Disagree" to "Completely Agree". The mean of the scores is calculated to determine the overall score.

    Time frame: Month 6

  6. Patient Assessment of Chronic Illness Care [PACIC]

    The Patient Assessment of Chronic Illness Care (PACIC) is scored by averaging the responses to all 20 items on the scale. The score ranges from 1 to 5, with higher scores indicating that patients feel more involved in their care and self-management.

    Time frame: Month 6

  7. Organizational Readiness for Implementing Change [ORIC]

    Organizational Readiness for Implementing Change (ORIC) is a 12-item instrument used to determine how well employees at an organization feel they can implement the change in processes required by a proposed intervention. Each item includes a Likert scale from 1 (Disagree) to 5 (Agree) - The range of each scale is -10 through 0 to +10. A negative scale score reflects an overall disagreement with items measuring the stage of change, whereas a positive score represents overall agreement.

    Time frame: Month 6

Other outcomes

  1. Number of clinic, urgent care and emergency department visits

    Number of clinic, urgent care and emergency department visits from Electronic Medical Records (both arms).

    Time frame: Month 6

  2. Patient self-reported home BP monitor use

    Patient self-reported home BP monitor use and self-management referrals from EMR (usual care group only).

    Time frame: Month 6

  3. Reasons for patient contact

    Reasons for patient contact (scheduled, unscheduled calls \[e.g., technical, intervention or safety related\]) (TM-HTN arm only)

    Time frame: Month 6

  4. patients with resistant hypertension

    Subgroup analysis in patients with resistant hypertension

    Time frame: Month 6

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Sep 2028, 22 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 22 months is close to that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2024
First posted
Sep 19, 2024
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Nov 2026
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Start date Oct 2026→Nov 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06593119
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Nov 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Camelia Singletary, MPH
Contact
Camelia.Singletary@Advocatehealth.org
336.713.7210
Yashashwi Pokharel, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion